Shares of Biocon were trading higher by 2% at Rs 457 on the BSE in early morning trade after Syngene International, research arm of biotechnology major, has received Securities Exchange Board of India’s (Sebi) approval to launch an initial public offer (IPO).
As per the draft papers, Syngene International plans to sell 22 million equity shares, including reservation of up to two million shares for Biocon shareholders, through an offer for sale, the PTI report suggests.